{
    "ticker": "NERV",
    "name": "Minerva Neurosciences, Inc.",
    "description": "Minerva Neurosciences, Inc. is a clinical-stage biopharmaceutical company dedicated to the development of innovative therapies for the treatment of neuropsychiatric and neurodegenerative disorders. Founded in 2013 and headquartered in Waltham, Massachusetts, Minerva focuses on addressing unmet medical needs in the field of mental health through rigorous scientific research and clinical development. The company's lead product candidate, MIN-101, is an investigational treatment for schizophrenia, and it aims to improve the quality of life for patients suffering from this debilitating condition. Minerva employs a science-driven approach and collaborates with leading academic institutions and research organizations to advance its clinical pipeline. The company's mission is to transform the landscape of psychiatric treatment, and it is committed to delivering safe and effective therapies that enhance patient outcomes and well-being. By leveraging advanced technologies and innovative methodologies, Minerva strives to bring hope to patients and families affected by mental health disorders.",
    "industry": [
        "Biopharmaceutical",
        "Healthcare"
    ],
    "headquarters": "Waltham, Massachusetts, USA",
    "founded": "2013",
    "website": "https://www.minervaneurosciences.com",
    "ceo": "Fred P. Fisher",
    "social_media": {
        "twitter": "https://twitter.com/MinervaNeuro",
        "linkedin": "https://www.linkedin.com/company/minerva-neurosciences/"
    },
    "investor_relations": "https://ir.minervaneurosciences.com",
    "key_executives": [
        {
            "name": "Fred P. Fisher",
            "position": "CEO"
        },
        {
            "name": "David P. O'Connor",
            "position": "CFO"
        }
    ],
    "product_categories": [
        {
            "category": "Drug Development",
            "products": [
                "MIN-101"
            ]
        }
    ],
    "seo": {
        "meta_title": "Minerva Neurosciences, Inc. | Innovative Neuropsychiatric Therapies",
        "meta_description": "Explore Minerva Neurosciences, Inc., a biopharmaceutical company focused on developing innovative treatments for neuropsychiatric disorders. Learn about our mission and product pipeline.",
        "keywords": [
            "Minerva Neurosciences",
            "Neuropsychiatry",
            "Schizophrenia",
            "MIN-101",
            "Biopharmaceutical",
            "Mental Health"
        ]
    },
    "faq": [
        {
            "question": "What is Minerva Neurosciences known for?",
            "answer": "Minerva Neurosciences is known for its development of therapies for neuropsychiatric disorders, particularly schizophrenia."
        },
        {
            "question": "Who is the CEO of Minerva Neurosciences?",
            "answer": "Fred P. Fisher is the CEO of Minerva Neurosciences, Inc."
        },
        {
            "question": "Where is Minerva Neurosciences headquartered?",
            "answer": "Minerva Neurosciences is headquartered in Waltham, Massachusetts, USA."
        },
        {
            "question": "What are Minerva's main products?",
            "answer": "Minerva's main product in development is MIN-101, aimed at treating schizophrenia."
        },
        {
            "question": "When was Minerva Neurosciences founded?",
            "answer": "Minerva Neurosciences was founded in 2013."
        }
    ],
    "competitors": [
        "ACAD",
        "PFE",
        "VRTX"
    ],
    "related_stocks": [
        "JNJ",
        "MRK",
        "ABBV",
        "GILD"
    ]
}